Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A method for evaluating a gastrointestinal tract may include receiving an electrical signal that includes data pertaining to motility in the gastrointestinal tract of a patient and analyzing one or more characteristics of the electrical signal relative to one or more respective thresholds indicative of an occurrence or an imminence of a condition of the gastrointestinal tract.

Abstract: A method for evaluating a gastrointestinal tract may include receiving an electrical signal that includes data pertaining to motility in the gastrointestinal tract of a patient and analyzing one or more characteristics of the electrical signal relative to one or more respective thresholds indicative of an occurrence or an imminence of a condition of the gastrointestinal tract.

Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A bypass device may include an elongate member extending from a proximal end toward a distal end, and a proximal opening and a distal opening coupled to one another by a lumen disposed through the elongate member. The bypass device also may include at least one port extending through a side surface of the elongate tubular member, wherein at least a portion of the bypass device may be bioabsorbable.

Abstract: A bypass device may include an elongate member extending from a proximal end toward a distal end, and a proximal opening and a distal opening coupled to one another by a lumen disposed through the elongate member. The bypass device also may include at least one port extending through a side surface of the elongate tubular member, wherein at least a portion of the bypass device may be bioabsorbable.

Abstract: Cryogenic biopsy assemblies are described herein that comprise a tissue acquisition device and cryogenic probe. Also disclosed are systems containing such cryogenic biopsy assemblies and methods cryogenic biopsy that employ such cryogenic biopsy assemblies.

Abstract: A system for treating a gastrointestinal tract may include a device configured to measure electrical activity at a plurality of locations within a gastrointestinal tract of a patient, a controller configured to compare the measured activity from the plurality of locations to a database of electrical activity corresponding to one or more gastric events, abnormalities, or dysrhythmias. The controller may be configured to determine one or more treatment locations based on the comparison, and cause the device to deliver therapy to the one or more treatment locations.

Abstract: A method for evaluating a gastrointestinal tract may include characterizing one or more disease parameters using objective measures obtained from imaging data of a gastrointestinal tract. The one or more disease parameters reflect a measure of at least one of lesions, ulcers, bleeding, stenosis, and vasculature. The method may also include using the one or more characterized disease parameters to classify a disease state.

Abstract: A method for evaluating a gastrointestinal tract may include receiving an electrical signal that includes data pertaining to motility in the gastrointestinal tract of a patient and analyzing one or more characteristics of the electrical signal relative to one or more respective thresholds indicative of an occurrence or an imminence of a condition of the gastrointestinal tract.

Abstract: A system for treating a gastrointestinal tract may include a device configured to measure electrical activity at a plurality of locations within a gastrointestinal tract of a patient, a controller configured to compare the measured activity from the plurality of locations to a database of electrical activity corresponding to one or more gastric events, abnormalities, or dysrhythmias. The controller may be configured to determine one or more treatment locations based on the comparison, and cause the device to deliver therapy to the one or more treatment locations.

Abstract: A device for causing hemostasis includes a sheet of mesh stretchable between an expanded and a retracted configuration, a size of the sheet in the retracted configuration being selected to cover a target tissue site; a spring mechanism coupled to the mesh, the spring mechanism moving between an expanded configuration and a retracted configuration when the mesh is moved between the expanded and retracted configurations; and a plurality of hooks coupled to the mesh and oriented to extend into tissue to lock the mesh in position when the mesh is placed in a desired position over the target tissue site in the expanded configuration. The hooks are lockingly engaging the target tissue so that, after the hooks have lockingly engaged the tissue, the spring mechanism reverts to the retracted configuration drawing the engaged portions of tissue radially inward.

Abstract: A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

Abstract: A bypass device may include an elongate member extending from a proximal end toward a distal end, and a proximal opening and a distal opening coupled to one another by a lumen disposed through the elongate member. The bypass device also may include at least one port extending through a side surface of the elongate tubular member, wherein at least a portion of the bypass device may be bioabsorbable.

Abstract: A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

Abstract: The present disclosure is directed to systems and methods for creating a drain within a duct of a patient's pancreatico-biliary system. The method may include positioning a first elongate member distally of a stricture within the duct, wherein a magnetic portion is disposed at or near a proximal end of the first elongate member. A second elongate member is positioned proximally of the stricture within the duct, wherein a magnetic portion is disposed at or near a distal end of the second elongate member. The proximal end of the first elongate member is spaced apart from the distal end of the second elongate member, and the magnetic portion of the first elongate member and the magnetic portion of the second elongate member are attracted to each other so that at least one of the first elongate member and the second elongate member is pulled into the stricture within the duct.

Abstract: The invention is directed to a stent including at least one member having a first portion and a second portion and at least one radiopaque connector joining the first portion to the second portion. In one or more embodiments, at least one radiopaque connector may form a first radiopaque pattern distinguishable from a second radiopaque pattern formed by at least one radiopaque marker. Methods for manufacturing a stent including at least two member portions connected by at least one radiopaque connector are also provided.